USPTO Examiner PIPIC ALMA - Art Unit 1617

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18582837POLYMERIC DISPERSANTS FROM PHENYL GLYCIDYL ETHERFebruary 2024April 2025Allow1411YesNo
18423852MULTI-LAYER HAEMOSTAT PATCH COMPRISING BETA-CHITINJanuary 2024June 2025Abandon1611NoNo
18470327ENCAPSULATION OF GASTRIC RESIDENCE SYSTEMSSeptember 2023December 2024Allow1420YesNo
18464906MAKEUP COMPOSITIONS FOR TREATING SKIN DEFECTSSeptember 2023March 2025Abandon1801NoNo
18242468CARBOHYDRATE CROSSLINKERSeptember 2023April 2025Abandon2030YesNo
18230438INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASESAugust 2023March 2025Abandon1910NoNo
18365074RINSE-OFF COMPOSITIONS AND USES THEREOF FOR DELIVERY OF ACTIVE AGENTSAugust 2023May 2025Abandon2210NoNo
18346895STERILIZATION OF SELF-ASSEMBLING PEPTIDES BY IRRADIATIONJuly 2023May 2024Allow1011YesNo
18256582DIFFUSER OF VOLATILE LIQUID SUBSTANCES EQUIPPED WITH A VAPOR PERMEABLE MEMBRANE, ACTIVATED AT THE TIME OF USEJune 2023February 2024Allow810NoNo
18143368ALBUMIN-BASED NON-COVALENT COMPLEXES AND METHODS OF USE THEREOFMay 2023March 2025Allow2220NoNo
18300281LONG ACTING, CONTINUOUS ORAL RELEASE FROM ORAL DISPERSING STRIPS (ODS) ADDRESSING THE NEED FOR HIGH DOSAGE OF ACTIVE INGREDIENTSApril 2023January 2025Abandon2131YesNo
18185099PROCESS FOR THE PREPARATION OF A COMPOSITION OF LIPOAMINO ACIDS AND DIOLSMarch 2023March 2025Abandon2520NoNo
18184439CARBOHYDRATE CROSSLINKERMarch 2023June 2023Allow310NoNo
18115511COMPOSITE TUBULAR MATERIAL PREPARED FROM EXTRACELLULAR MATRIX AND SYNTHETIC POLYMER, AND PREPARATION METHOD THEREOFFebruary 2023July 2024Allow1721YesNo
18098239method for treating deep wounds of dermis and/or below tissueJanuary 2023October 2024Abandon2140YesNo
18074244STERILIZATION OF SELF-ASSEMBLING PEPTIDES BY IRRADIATIONDecember 2022April 2023Allow410NoNo
18071282CARBOHYDRATE CROSSLINKERNovember 2022February 2023Allow310NoNo
18056310METHOD FOR TERMINATING CANCER CELLS WITH AN AZOLE-BASED COMPOUNDNovember 2022June 2023Allow720YesNo
17983330Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the SameNovember 2022September 2023Abandon1010NoNo
17981445STERILIZATION OF SELF-ASSEMBLING PEPTIDES BY IRRADIATIONNovember 2022April 2023Allow510YesNo
18048423HYBRID CARRIERS FOR NUCLEIC ACID CARGOOctober 2022January 2024Abandon1501NoNo
17935300PROMOTING ENDOTHELIAL CELL AFFINITY AND ANTITHROMBOGENICITY OF POLYTETRAFLUOROETHYLENE (PTFE) BY MUSSEL-INSPIRED MODIFICATION AND RGD/HEPARIN GRAFTINGSeptember 2022June 2023Allow810YesNo
17856198LUBRICATING BLOCK COPOLYMERS AND THEIR USE AS BIOMIMETIC BOUNDARY LUBRICANTSJuly 2022March 2025Allow3221YesNo
17845141SETTABLE BONE VOID FILLERJune 2022October 2024Allow2820YesNo
17831392ELECTROACTIVE BIOADHESIVE COMPOSITIONSJune 2022December 2023Allow1810NoNo
17662923FUNCTIONAL MICROSCAFFOLD THAT CAN BE MAGNETICALLY ACTUATED AND MANUFACTURING METHOD THEREFORMay 2022June 2025Abandon3710NoNo
17740192OPHTHALMIC DRUG SUSTAINED RELEASE FORMULATION AND USES THEREOFMay 2022December 2023Allow1920NoNo
17774103COMBINED PREPARATION AND METHOD FOR COMBATING FUNGUS-GROWING ANTSMay 2022May 2025Abandon3701NoNo
17717837METHOD FOR FORMING ELASTIC FILM STRETCHABLE STRUCTURE AND ABSORBENT ARTICLEApril 2022March 2024Allow2400NoNo
17718169HYDROPHILIC MEDICAL PRODUCTS AND HYDRATION MEDIUMS FOR HYDRATING THE SAMEApril 2022January 2025Allow3320NoNo
17762889ACTIVE COMPOUND COMBINATIONS COMPRISING FATTY ACIDSMarch 2022May 2025Abandon3810NoNo
17638989METHOD FOR CONTROLLING GROWTH OF GLYPHOSATE-TOLERANT PLANTSFebruary 2022June 2025Abandon4010NoNo
17633050MOLECULAR COMPLEXESFebruary 2022May 2025Abandon4010NoNo
17524801SELF-REINFORCED STARCH-BASED MULTIFUNCTIONAL MATERIALS AND PROCESSING METHOD THEREOFNovember 2021May 2022Allow611YesNo
17520987Devices and Methods for Nerve RegenerationNovember 2021March 2023Allow1610NoNo
17519368Microgel CompositionsNovember 2021March 2025Abandon4021NoNo
17377124MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONSJuly 2021May 2024Allow3420NoNo
17417628METHOD FOR CONTROLLING WEEDJune 2021February 2025Abandon4410NoNo
17303630METHOD OF LONG-TERM PRESERVATION OF CHEMICAL AND BIOLOGICAL SPECIES USING SUGAR GLASSESJune 2021April 2025Abandon4760NoNo
17335643POLYMERS WITH ANTIMICROBIAL FUNCTIONALITIESJune 2021March 2023Allow2210YesNo
17294751SYNERGISTIC HERBICIDE COMPOSITION OF BROAD-SPECTRUM FOR THE CONTROL OF WEEDS IN AGRICULTURAL CULTURES, USE OF SUCH COMPOSITION FOR PREPARATION OF PRODUCT, PRODUCT AND METHOD OF APPLICATIONMay 2021December 2023Allow3131YesNo
17315476Pesticidal Compositions and Related MethodsMay 2021July 2022Allow1421YesNo
17291992Compositions and Methods for Modulating Root GrowthMay 2021August 2024Allow3921YesNo
17308139METHOD FOR MAKING A CONJUGATE AZOLE-BASED SURFACE MODIFIED SILICON DIOXIDE NANOPARTICLEMay 2021November 2022Allow1810NoNo
17291107COMPOSITIONS COMPRISING PYRIDINE CARBOXYLATE HERBICIDES AND AZOLE CARBOXYLATE SAFENERSMay 2021May 2025Allow4841YesNo
17306456ANTIMICROBIAL COATING COMPOSITIONSMay 2021July 2023Abandon2610NoNo
17290556PESTICIDALLY ACTIVE AZOLE-AMIDE COMPOUNDSApril 2021July 2024Allow3810NoNo
17290232COMPOSITIONS COMPRISING HALAUXIFEN AND OTHER HERBICIDES AND METHODS THEREOFApril 2021November 2024Abandon4211NoNo
17285321Treatment of Plants or Fungi Against DiseaseApril 2021June 2024Abandon3810NoNo
17229004METHOD FOR MANUFACTURING MEDICAL SPONGE FOR ORTHOPEDIC TREATMENT BY UNILATERAL PRESSINGApril 2021August 2021Allow410NoNo
17222453LINEAR POLYOL STABILIZED POLYFLUOROACRYLATE COMPOSITIONSApril 2021April 2023Abandon2410NoNo
17217911STERILIZATION OF SELF-ASSEMBLING PEPTIDES BY IRRADIATIONMarch 2021September 2022Allow1821YesNo
17215700ANTIMICROBIAL POLYMERS CAPABLE OF SUPRAMOLECULAR ASSEMBLYMarch 2021January 2023Allow2110YesNo
17214788METHOD OF PREVENTING MICROBES IN DISPOSABLE PRODUCTSMarch 2021February 2024Abandon3401YesNo
17204679PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASESMarch 2021November 2023Allow3220YesNo
17204093Tissue-Adhesive MaterialMarch 2021June 2023Allow2720YesNo
17188820MAKEUP COMPOSITIONS FOR TREATING SKIN DEFECTSMarch 2021September 2023Abandon3101NoNo
17184152NON-LINEAR MULTIBLOCK COPOLYMER-DRUG CONJUGATES FOR THE DELIVERY OF ACTIVE AGENTSFebruary 2021January 2023Allow2310NoNo
17270721COMPOSITION FOR COATING AND ENCRUSTING INDUSTRIAL OR NON-INDUSTRIAL SEEDS FOR BIOLOGICAL CONTROL OF PHYTONEMATODE AND PHYTOPATHOGENIC SPECIESFebruary 2021September 2024Abandon4320NoNo
17168998RINSE-OFF COMPOSITIONS AND USES THEREOF FOR DELIVERY OF ACTIVE AGENTSFebruary 2021January 2024Abandon3520NoNo
17265297DISPOSABLE WEARABLE ABSORBENT ARTICLEFebruary 2021October 2021Allow901NoNo
17248501METHOD OF TREATING A VIRAL INFECTIONJanuary 2021July 2023Abandon3040NoNo
17262790METHOD FOR PATHOGENS, MICROORGANISMS, AND PARASITES INACTIVATIONJanuary 2021June 2024Abandon4110NoNo
17154251ALBUMIN-BASED NON-COVALENT COMPLEXES AND METHODS OF USE THEREOFJanuary 2021May 2023Abandon2810NoNo
17260724COSMETIC COMPOSITION FOR INCREASING SKIN EXFOLIATIONJanuary 2021August 2024Abandon4320YesNo
17136709UTILIZING POLYMERS AND ANTIBIOTICS TO ENHANCE ANTIMICROBIAL ACTIVITY AND INHIBIT ANTIBIOTIC RESISTANCEDecember 2020July 2023Allow3110YesNo
17256354THERAPEUTIC HYDROGELS AND CONTACT LENS FOR CORNEAL MELTINGDecember 2020January 2024Allow3610YesNo
17251897METHOD OF IMPROVING HEALTH AND ROOTING OF HARDWOOD TREESDecember 2020September 2024Abandon4520NoNo
17058368BIFUNCTIONAL MODIFIED BIOPOLYMER BASED POLYMERS AND HYDROGELS OBTAINABLE FROM SUCH BIFUNCTIONAL MODIFIED BIOPOLYMER BASED POLYMERSNovember 2020June 2025Abandon5541NoNo
17102109CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTSNovember 2020April 2025Abandon5340YesNo
16953811MAKEUP COMPOSITIONS FOR TREATING SKIN DEFECTSNovember 2020March 2023Abandon2810NoNo
17057314HOT-MELT ADHESIVES COMPRISING A BIMODAL POLYMER COMPOSITION FORMED BY POLYOLEFINS HAVING LOW STEREOSPECIFICITYNovember 2020January 2022Allow1420YesNo
17055973HYDROPHILIC MEDICAL PRODUCTS AND HYDRATION MEDIUMS FOR HYDRATING THE SAMENovember 2020February 2022Allow1510NoNo
17092855SKIN-LIKE CONDOMS HAVING ACTIVE INGREDIENTS TO ENHANCE A MALE ERECTION AND A FEMALE AROUSALNovember 2020August 2022Allow2200YesNo
17090543SKIN-LIKE CONDOMS HAVING ACTIVE INGREDIENTS TO ENHANCE A MALE ERECTION AND A FEMALE AROUSALNovember 2020August 2022Allow2200YesNo
17048869USE OF A SUBSTRATE COATING FOR DECREASING LEAKAGE OF MATTEROctober 2020April 2023Allow3010YesNo
17072771CHEMICAL COMPOSITIONS WITH ANTIMICROBIAL FUNCTIONALITYOctober 2020September 2022Allow2310YesNo
17071548PLANT IMMUNITY INDUCTION METHOD AND PLANT IMMUNITY INDUCTION AGENTOctober 2020March 2024Allow4121YesNo
17035860COPOLYMER, WETTING AGENT, MEDICAL DEVICE, AND METHOD FOR PRODUCING SAMESeptember 2020January 2023Allow2710NoNo
16978509SPREADING AGENT FOR AGROCHEMICALS, AND AGROCHEMICAL SPRAY SOLUTIONSeptember 2020January 2024Allow4020YesNo
17011492SELF-EMULSIFYING NANO-EMULSIONSSeptember 2020December 2023Abandon3930NoNo
17008062METHOD OF STOPPING CSF LEAKS AND APPARATUS THEREFORAugust 2020October 2022Allow2611YesNo
16990711ABUSE DETERRENT IMMEDIATE RELEASE FORMULATIONS COMPRISING NON-CELLULOSE POLYSACCHARIDESAugust 2020October 2022Allow2620YesNo
16969124MULTI-BLOCK COPOLYMER COMPOSITIONSAugust 2020December 2024Allow5231YesNo
16967621ALPHA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOFAugust 2020February 2025Allow5441YesNo
16967351PEDIATRIC NIRAPARIB FORMULATIONS AND PEDIATRIC TREATMENT METHODSAugust 2020March 2024Abandon4410NoNo
16967283ALPHA POLYGLUTAMATED RALTITREXED AND USES THEREOFAugust 2020January 2025Allow5321NoNo
16966357BRANCHED POLY(AMINO ACID) ANTIMICROBIAL AGENTS AND USE THEREOFJuly 2020June 2025Abandon5831YesNo
16935110Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the SameJuly 2020August 2022Allow2410NoNo
16934474Thermoresponsive Injectable Microparticles-Gel Composites with Low Dose of Recombinant BMP-9 and VEGF for Bone RepairJuly 2020December 2021Allow1730YesNo
169626471,2,3',5'-TETRAHYDRO-2'H-SPIRO[INDOLE-3,1'-PYRROLO[3,4-C]PYRROLE]-2,3'-DIONE COMPOUNDS AS THERAPEUTIC AGENTS ACTIVATING TP53July 2020June 2025Allow5931YesNo
16923434SYNTHESIS AND FORMULATION OF LIGNIN DERIVED COMPOUNDS AS TREATMENT OF PLANT DISEASESJuly 2020September 2022Allow2610YesNo
16917087Methods of Increasing the Volume of a Fiber, Such as Mammalian Hair, and/or Altering the Structure of a Fiber with a Chitosan Polyelectrolyte ComplexJune 2020May 2024Allow4641NoYes
16957532COMPOSITION FOR CARING FOR AND/OR MAKING UP KERATIN MATERIALSJune 2020July 2024Abandon4951NoNo
16910447METHOD OF TREATING SEVERE FORMS OF PULMONARY HYPERTENSIONJune 2020February 2025Allow5641YesNo
16906618TOPICAL FOAM COMPOSITIONJune 2020November 2021Abandon1720YesNo
16956420NEW COMPOSITION OF LIPOAMINO ACIDS AND DIOLS, PROCESS FOR THE PREPARATION THEREOF, AND COSMETIC OR PHARMACEUTICAL COMPOSITION RESULTING THEREFROMJune 2020July 2023Abandon3721NoNo
16905349MULTI-LAYER HAEMOSTAT PATCH COMPRISING BETA-CHITINJune 2020February 2024Abandon4421YesYes
16954627ROTIGOTINE-CONTAINING PATCHJune 2020January 2023Allow3120YesNo
16899774SILK/PET MIX-WOVEN SCAFFOLD AND PREPARATION METHOD AND USE THEREOFJune 2020January 2022Allow2011YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PIPIC, ALMA.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
23
Examiner Affirmed
18
(78.3%)
Examiner Reversed
5
(21.7%)
Reversal Percentile
33.7%
Lower than average

What This Means

With a 21.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
73
Allowed After Appeal Filing
14
(19.2%)
Not Allowed After Appeal Filing
59
(80.8%)
Filing Benefit Percentile
20.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 19.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner PIPIC, ALMA - Prosecution Strategy Guide

Executive Summary

Examiner PIPIC, ALMA works in Art Unit 1617 and has examined 711 patent applications in our dataset. With an allowance rate of 56.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner PIPIC, ALMA's allowance rate of 56.7% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by PIPIC, ALMA receive 2.48 office actions before reaching final disposition. This places the examiner in the 85% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by PIPIC, ALMA is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +59.5% benefit to allowance rate for applications examined by PIPIC, ALMA. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 15.8% of applications are subsequently allowed. This success rate is in the 7% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 32.5% of cases where such amendments are filed. This entry rate is in the 40% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 14.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 23% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 55.8% of appeals filed. This is in the 23% percentile among all examiners. Of these withdrawals, 44.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 43.8% are granted (fully or in part). This grant rate is in the 47% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.